{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:12:41Z","timestamp":1770973961949,"version":"3.50.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11095-008-9812-z","type":"journal-article","created":{"date-parts":[[2009,1,27]],"date-time":"2009-01-27T16:55:00Z","timestamp":1233075300000},"page":"770-784","source":"Crossref","is-referenced-by-count":55,"title":["Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide"],"prefix":"10.1007","volume":"26","author":[{"given":"Saffar","family":"Mansoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Cristina","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,28]]},"reference":[{"key":"9812_CR1","volume-title":"Textbook of ocular pharmacology","author":"K. Kooner","year":"1997","unstructured":"K. Kooner, T. Zimmerman, and M. Sharir. Textbook of ocular pharmacology. Lippincott-Raven, Philadelphia, 1997."},{"key":"9812_CR2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/00912700022009413","volume":"40","author":"D. Argenti","year":"2000","unstructured":"D. Argenti, B. K. Jensen, R. Hensel, K. Bordeaux, R. Schleimer, C. Bickel, and D. Heald. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J. Clin. Pharmacol. 40:770\u2013780 (2000). doi: 10.1177\/00912700022009413 .","journal-title":"J. Clin. Pharmacol."},{"key":"9812_CR3","first-page":"698","volume":"71","author":"K. Kreines","year":"1975","unstructured":"K. Kreines, and I. C. Weinberg. The selection of adrenocorticosteroid preparations. Ohio State Med. J. 71:698 (1975). 703\u2013706.","journal-title":"Ohio State Med. J."},{"key":"9812_CR4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/00912700022009413","volume":"40","author":"B. Jensen","year":"2000","unstructured":"B. Jensen, D. Argenti, and R. Hensel. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J. Clin. Pharmacol. 40:770\u2013780 (2000). doi: 10.1177\/00912700022009413 .","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl","key":"9812_CR5","first-page":"153","volume":"11","author":"A. Boyd","year":"1992","unstructured":"A. Boyd, I. G. Duguid, and T. E. Mandel. Adhesion molecules are expressed in the human retina and choroid. Curr. Eye Res. 11(Suppl):153\u2013159 (1992).","journal-title":"Curr. Eye Res."},{"key":"9812_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00015559850135751","volume":"78","author":"J. Veraart","year":"1998","unstructured":"J. Veraart, A. Sommer, and M. Neumann. Evaluation of the vasoconstrictive effects of topical steroids by laser-Dopplerperfusion-imaging. Acta Derm.-Venereol. 78:15\u201318 (1998). doi: 10.1080\/00015559850135751 .","journal-title":"Acta Derm.-Venereol."},{"key":"9812_CR7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/0024-3205(94)90093-0","volume":"55","author":"R. A. Adler","year":"1994","unstructured":"R. A. Adler, S. A. Naumann, A. Mansouri, R. J. Krieg Jr., K. Latta, and K. M. Sanders. Anti-proliferative effects of deflazacort on Nb2 cells as quantitated by formazan production. Life Sci. 55:1823\u2013831 (1994). doi: 10.1016\/0024-3205(94)90093-0 .","journal-title":"Life Sci."},{"key":"9812_CR8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.preteyeres.2005.01.004","volume":"24","author":"J. B. Jonas","year":"2005","unstructured":"J. B. Jonas, I. Kreissig, and R. Degenring. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog. Retin. Eye Res. 24:587\u2013611 (2005). doi: 10.1016\/j.preteyeres.2005.01.004 .","journal-title":"Prog. Retin. Eye Res."},{"key":"9812_CR9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00005392-199707000-00084","volume":"158","author":"J. Sosnowski","year":"1997","unstructured":"J. Sosnowski, C. Stetter-Neel, D. Cole, J. P. Durham, and M. G. Mawhinney. Protein kinase C mediated anti-proliferative glucocorticoid-sphinganine synergism in cultured Pollard III prostate tumor cells. J. Urol. 158:269\u2013274 (1997). doi: 10.1097\/00005392-199707000-00084 .","journal-title":"J. Urol."},{"key":"9812_CR10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.icu.0000120711.35941.76","volume":"15","author":"T. A. Ciulla","year":"2004","unstructured":"T. A. Ciulla, J. D. Walker, D. S. Fong, and M. H. Criswell. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr. Opin. Ophthalmol. 15:211\u2013220 (2004). doi: 10.1097\/01.icu.0000120711.35941.76 .","journal-title":"Curr. Opin. Ophthalmol."},{"key":"9812_CR11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/02713680500263598","volume":"30","author":"E. A. Felinski","year":"2005","unstructured":"E. A. Felinski, and D. A. Antonetti. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr. Eye Res. 30:949\u2013957 (2005). doi: 10.1080\/02713680500263598 .","journal-title":"Curr. Eye Res."},{"key":"9812_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0014-2999(97)01464-7","volume":"341","author":"M. Nauck","year":"1998","unstructured":"M. Nauck, G. Karakiulakis, A. P. Perruchoud, E. Papakonstantinou, and M. Roth. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol. 341:309\u2013315 (1998). doi: 10.1016\/S0014-2999(97)01464-7 .","journal-title":"Eur. J. Pharmacol."},{"key":"9812_CR13","first-page":"119","volume":"8","author":"H. E. Grossniklaus","year":"2002","unstructured":"H. E. Grossniklaus, J. X. Ling, T. M. Wallace, S. Dithmar, D. H. Lawson, C. Cohen, V. M. Elner, S. G. Elner, and P. Sternberg Jr. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol. Vis. 8:119\u2013126 (2002).","journal-title":"Mol. Vis."},{"key":"9812_CR14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1172\/JCI118815","volume":"98","author":"J. McLaren","year":"1996","unstructured":"J. McLaren, A. Prentice, D. S. Charnock-Jones, S. A. Millican, K. H. Muller, A. M. Sharkey, and S. K. Smith. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J. Clin. Invest. 98:482\u2013489 (1996). doi: 10.1172\/JCI118815 .","journal-title":"J. Clin. Invest."},{"key":"9812_CR15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1083\/jcb.135.2.497","volume":"135","author":"A. Del Maschio","year":"1996","unstructured":"A. Del Maschio, A. Zanetti, M. Corada, Y. Rival, L. Ruco, M. G. Lampugnani, and E. Dejana. Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J. Cell. Biol. 135:497\u2013510 (1996). doi: 10.1083\/jcb.135.2.497 .","journal-title":"J. Cell. Biol."},{"key":"9812_CR16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9440(10)64869-9","volume":"160","author":"A. M. Joussen","year":"2002","unstructured":"A. M. Joussen, V. Poulaki, W. Qin, B. Kirchhof, N. Mitsiades, S. J. Wiegand, J. Rudge, G. D. Yancopoulos, and A. P. Adamis. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am. J. Pathol. 160:501\u2013509 (2002).","journal-title":"Am. J. Pathol."},{"key":"9812_CR17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.0022-3042.2001.00740.x","volume":"80","author":"D. A. Antonetti","year":"2002","unstructured":"D. A. Antonetti, E. B. Wolpert, L. DeMaio, N. S. Harhaj, and R. C. Scaduto Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. 80:667\u2013677 (2002). doi: 10.1046\/j.0022-3042.2001.00740.x .","journal-title":"J. Neurochem."},{"key":"9812_CR18","first-page":"1653","volume":"42","author":"A. Wenzel","year":"2001","unstructured":"A. Wenzel, C. Grimm, M. W. Seeliger, G. Jaissle, F. Hafezi, R. Kretschmer, E. Zrenner, and C. E. Reme. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest. Ophthalmol. Vis. Sci. 42:1653\u20131659 (2001).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"9812_CR19","unstructured":"F. Ali. A review of diabetic macular edema. Digit. J. Ophthalmol. (2002)."},{"key":"9812_CR20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(01)00200-9","volume":"52","author":"R. Herrero-Vanrell","year":"2001","unstructured":"R. Herrero-Vanrell, and M. F. Refojo. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52:5\u201316 (2001). doi: 10.1016\/S0169-409X(01)00200-9 .","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9812_CR21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1023\/A:1011060705599","volume":"18","author":"J. V. Aukunuru","year":"2001","unstructured":"J. V. Aukunuru, G. Sunkara, N. Bandi, W. B. Thoreson, and U. B. Kompella. Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm. Res. 18:565\u2013572 (2001). doi: 10.1023\/A:1011060705599 .","journal-title":"Pharm. Res."},{"key":"9812_CR22","unstructured":"N. J. Mangini, and B. G. Kennedy. Native and cultured human RPE express P-glycoprotein, ARVO Annual Meeting, 2002."},{"key":"9812_CR23","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","volume":"57","author":"P. M. Hughes","year":"2005","unstructured":"P. M. Hughes, O. Olejnik, J. E. Chang-Lin, and C. G. Wilson. Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 57:2010\u20132032 (2005). doi: 10.1016\/j.addr.2005.09.004 .","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9812_CR24","volume-title":"Drug delivery to the posterior segment","author":"V. H. L. Lee","year":"1998","unstructured":"V. H. L. Lee, K. J. Pince, D. A. Frambach, and B. T. Martini. Drug delivery to the posterior segment. Oxford University Press, New York, 1998."},{"key":"9812_CR25","first-page":"491","volume":"65","author":"P. Quiroga","year":"1993","unstructured":"P. Quiroga, A. Dominquez, and M. Jareno. El tratamento de enfermedads medicas con triamcinolone intravitrea. Arch. Doc. Esp. Oftalmol. 65:491\u2013498 (1993).","journal-title":"Arch. Doc. Esp. Oftalmol."},{"key":"9812_CR26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/0002-9394(81)90013-1","volume":"91","author":"M. Bessler","year":"1981","unstructured":"M. Bessler, B. W. McCuen, and Y. Tano. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am. J. Ophthalmol. 91:785\u2013788 (1981).","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00006982-200507000-00002","volume":"25","author":"H. S. Chin","year":"2005","unstructured":"H. S. Chin, T. S. Park, Y. S. Moon, and J. H. Oh. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25:556\u2013560 (2005). doi: 10.1097\/00006982-200507000-00002 .","journal-title":"Retina"},{"key":"9812_CR28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.survophthal.2007.06.004","volume":"52","author":"C. M. Jermak","year":"2007","unstructured":"C. M. Jermak, J. T. Dellacroce, J. Heffez, and G. A. Peyman. Triamcinolone acetonide in ocular therapeutics. Surv. Ophthalmol. 52:503\u2013522 (2007). doi: 10.1016\/j.survophthal.2007.06.004 .","journal-title":"Surv. Ophthalmol."},{"key":"9812_CR29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.survophthal.2007.12.005","volume":"53","author":"M. A. Cunningham","year":"2008","unstructured":"M. A. Cunningham, J. L. Edelman, and S. Kaushal. Intravitreal steroids for macular edema: the past, the present, and the future. Surv. Ophthalmol. 53:139\u2013149 (2008). doi: 10.1016\/j.survophthal.2007.12.005 .","journal-title":"Surv. Ophthalmol."},{"key":"9812_CR30","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","volume":"91","author":"R. Klein","year":"1984","unstructured":"R. Klein, B. E. Klein, S. E. Moss, M. D. Davis, and D. L. DeMets. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 91:1464\u20131474 (1984).","journal-title":"Ophthalmology"},{"key":"9812_CR31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000098257","volume":"221","author":"C. H. Meyer","year":"2007","unstructured":"C. H. Meyer. Current treatment approaches in diabetic macular edema. Ophthalmologica. 221:118\u2013131 (2007). doi: 10.1159\/000098257 .","journal-title":"Ophthalmologica"},{"key":"9812_CR32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/08820530390895262","volume":"18","author":"F. Bandello","year":"2003","unstructured":"F. Bandello, R. Pognuz, A. Polito, A. Pirracchio, F. Menchini, and M. Ambesi. Diabetic macular edema: classification, medical and laser therapy. Semin. Ophthalmol. 18:251\u2013258 (2003). doi: 10.1080\/08820530390895262 .","journal-title":"Semin. Ophthalmol."},{"key":"9812_CR33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1600-0420.2006.00712_39.x","volume":"84","author":"B. Sander","year":"2006","unstructured":"B. Sander. Diabetic macular edema evaluated by optical coherence tomography. Acta. Ophthalmol. Scand. 84:90 (2006). doi: 10.1111\/j.1600-0420.2006.00712_39.x .","journal-title":"Acta. Ophthalmol. Scand."},{"key":"9812_CR34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/jop.2007.0080","volume":"24","author":"M. Colucciello","year":"2008","unstructured":"M. Colucciello. Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results. J. Ocul. Pharmacol. Ther. 24:15\u201324 (2008). doi: 10.1089\/jop.2007.0080 .","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"9812_CR35","unstructured":"J. A. Tielsch. Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older, Prevent Blindness America. Schaumburg, IL: Prevent Blindness, 1994."},{"key":"9812_CR36","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.addr.2005.09.002","volume":"57","author":"P. H. O. Olejnik","year":"2005","unstructured":"P. H. O. Olejnik. Drug delivery strategies to treat age-related macular degeneration. Adv. Drug Deliv. Rev. 57:1991\u20131993 (2005). doi: 10.1016\/j.addr.2005.09.002 .","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9812_CR37","first-page":"460","volume":"13","author":"L. P. Iu","year":"2007","unstructured":"L. P. Iu, and A. K. Kwok. An update of treatment options for neovascular age-related macular degeneration. Hong Kong Med. J. 13:460\u2013470 (2007).","journal-title":"Hong Kong Med. J."},{"key":"9812_CR38","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(97)30079-7","volume":"104","author":"J. S. Sunness","year":"1997","unstructured":"J. S. Sunness, G. S. Rubin, C. A. Applegate, N. M. Bressler, M. J. Marsh, B. S. Hawkins, and D. Haselwood. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology 104:1677\u20131691 (1997).","journal-title":"Ophthalmology"},{"key":"9812_CR39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/IAE.0b013e31817082d7","volume":"28","author":"C. N. Singh","year":"2008","unstructured":"C. N. Singh, and D. A. Saperstein. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 28:789\u2013793 (2008). doi: 10.1097\/IAE.0b013e31817082d7 .","journal-title":"Retina"},{"key":"9812_CR40","doi-asserted-by":"crossref","unstructured":"A. Frimpong-Boateng, A. Bunse, F. Rufer, and J. Roider. Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients. Acta Ophthalmol. 1\u20135 (2008).","DOI":"10.1111\/j.1755-3768.2008.01213.x"},{"key":"9812_CR41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/bjo.2007.125823","volume":"92","author":"G. Weigert","year":"2008","unstructured":"G. Weigert, S. Michels, S. Sacu, A. Varga, F. Prager, W. Geitzenauer, and U. Schmidt-Erfurth. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br. J. Ophthalmol. 92:356\u2013360 (2008). doi: 10.1136\/bjo.2007.125823 .","journal-title":"Br. J. Ophthalmol."},{"key":"9812_CR42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10456-007-9069-x","volume":"10","author":"J. Bradley","year":"2007","unstructured":"J. Bradley, M. Ju, and G. S. Robinson. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141\u2013148 (2007). doi: 10.1007\/s10456-007-9069-x .","journal-title":"Angiogenesis"},{"key":"9812_CR43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.preteyeres.2007.03.002","volume":"26","author":"U. M. Schmidt-Erfurth","year":"2007","unstructured":"U. M. Schmidt-Erfurth, and C. Pruente. Management of neovascular age-related macular degeneration. Prog. Retin. Eye Res. 26:437\u2013451 (2007). doi: 10.1016\/j.preteyeres.2007.03.002 .","journal-title":"Prog. Retin. Eye Res."},{"key":"9812_CR44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1755-3768.2007.00979.x","volume":"85","author":"U. M. Schmidt-Erfurth","year":"2007","unstructured":"U. M. Schmidt-Erfurth, G. Richard, A. Augustin, W. G. Aylward, F. Bandello, B. Corcostegui, J. Cunha-Vaz, A. Gaudric, A. Leys, and R. O. Schlingemann. Guidance for the treatment of neovascular age-related macular degeneration. Acta. Ophthalmol. Scand. 85:486\u2013494 (2007). doi: 10.1111\/j.1755-3768.2007.00979.x .","journal-title":"Acta. Ophthalmol. Scand."},{"key":"9812_CR45","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.ophtha.2005.09.007","volume":"112","author":"U. Schmidt-Erfurth","year":"2005","unstructured":"U. Schmidt-Erfurth, M. Niemeyer, W. Geitzenauer, and S. Michels. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 112:2061\u20132069 (2005). doi: 10.1016\/j.ophtha.2005.09.007 .","journal-title":"Ophthalmology"},{"key":"9812_CR46","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1167\/iovs.02-1115","volume":"44","author":"U. Schmidt-Erfurth","year":"2003","unstructured":"U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G. O. Naumann. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 44:4473\u20134480 (2003). doi: 10.1167\/iovs.02-1115 .","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"9812_CR47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archopht.121.5.667","volume":"121","author":"M. C. Gillies","year":"2003","unstructured":"M. C. Gillies, J. M. Simpson, W. Luo, P. Penfold, A. B. Hunyor, W. Chua, P. Mitchell, and F. Billson. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch. Ophthalmol. 121:667\u2013673 (2003). doi: 10.1001\/archopht.121.5.667 .","journal-title":"Arch. Ophthalmol."},{"key":"9812_CR48","doi-asserted-by":"crossref","unstructured":"C. Durairaj, J. C. Shah, S. Senapati, and U. B. Kompella. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure\u2013pharmacokinetic relationships (QSPKR). Pharm Res (2008). doi: 10.1007\/s11095-008-9728-7 .","DOI":"10.1007\/s11095-008-9728-7"},{"key":"9812_CR49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00006982-200605000-00005","volume":"26","author":"H. Kim","year":"2006","unstructured":"H. Kim, K. G. Csaky, L. Gravlin, P. Yuan, R. J. Lutz, P. M. Bungay, G. Tansey, D. E. F. Monasterio, G. K. Potti, G. Grimes, and M. R. Robinson. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina 26:523\u2013530 (2006). doi: 10.1097\/00006982-200605000-00005 .","journal-title":"Retina"},{"key":"9812_CR50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-5224.2000.00117.x","volume":"3","author":"B. C. Gilger","year":"2000","unstructured":"B. C. Gilger, E. Malok, T. Stewart, P. Ashton, T. Smith, G. J. Jaffe, and J. B. Allen. Long-term effect on the equine eye of an intravitreal device used for sustained release of cyclosporine A. Vet. Ophthalmol. 3:105\u2013110 (2000). doi: 10.1046\/j.1463-5224.2000.00117.x .","journal-title":"Vet. Ophthalmol."},{"key":"9812_CR51","unstructured":"B. D. Kuppermann. Implants can deliver corticosteroids, pharmacologic agents, Retina Today, 2007, pp. 27\u201331."},{"key":"9812_CR52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","volume":"125","author":"B. D. Kuppermann","year":"2007","unstructured":"B. D. Kuppermann, M. S. Blumenkranz, J. A. Haller, G. A. Williams, D. V. Weinberg, C. Chou, and S. M. Whitcup. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125:309\u2013317 (2007). doi: 10.1001\/archopht.125.3.309 .","journal-title":"Arch. Ophthalmol."},{"key":"9812_CR53","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ajo.2004.10.052","volume":"139","author":"S. K. Seah","year":"2005","unstructured":"S. K. Seah, R. Husain, G. Gazzard, M. C. Lim, S. T. Hoh, F. T. Oen, and T. Aung. Use of surodex in phacotrabeculectomy surgery. Am. J. Ophthalmol. 139:927\u2013928 (2005). doi: 10.1016\/j.ajo.2004.10.052 .","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jcrs.2003.08.028","volume":"30","author":"A. C. Wadood","year":"2004","unstructured":"A. C. Wadood, A. M. Armbrecht, P. A. Aspinall, and B. Dhillon. Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification. J. Cataract. Refract. Surg. 30:761\u2013768 (2004). doi: 10.1016\/j.jcrs.2003.08.028 .","journal-title":"J. Cataract. Refract. Surg."},{"key":"9812_CR55","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","volume":"113","author":"G. J. Jaffe","year":"2006","unstructured":"G. J. Jaffe, D. Martin, D. Callanan, P. A. Pearson, B. Levy, and T. Comstock. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113:1020\u20131027 (2006). doi: 10.1016\/j.ophtha.2006.02.021 .","journal-title":"Ophthalmology"},{"key":"9812_CR56","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.addr.2006.07.026","volume":"58","author":"J. L. Bourges","year":"2006","unstructured":"J. L. Bourges, C. Bloquel, A. Thomas, F. Froussart, A. Bochot, F. Azan, R. Gurny, D. BenEzra, and F. Behar-Cohen. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug. Deliv. Rev. 58:1182\u20131202 (2006). doi: 10.1016\/j.addr.2006.07.026 .","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"9812_CR57","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1073\/pnas.0600236103","volume":"103","author":"P. A. Sieving","year":"2006","unstructured":"P. A. Sieving, R. C. Caruso, W. Tao, H. R. Coleman, D. J. Thompson, K. R. Fullmer, and R. A. Bush. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl. Acad. Sci. U. S. A. 103:3896\u20133901 (2006). doi: 10.1073\/pnas.0600236103 .","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"9812_CR58","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/14712598.6.7.717","volume":"6","author":"W. Tao","year":"2006","unstructured":"W. Tao. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin. Biol. Ther. 6:717\u2013726 (2006). doi: 10.1517\/14712598.6.7.717 .","journal-title":"Expert Opin. Biol. Ther."},{"key":"9812_CR59","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9394(98)00443-7","volume":"127","author":"J. I. Lim","year":"1999","unstructured":"J. I. Lim, R. A. Wolitz, A. H. Dowling, H. R. Bloom, A. R. Irvine, and D. M. Schwartz. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. 127:288\u2013293 (1999). doi: 10.1016\/S0002-9394(98)00443-7 .","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.preteyeres.2004.02.003","volume":"23","author":"T. Yasukawa","year":"2004","unstructured":"T. Yasukawa, Y. Ogura, Y. Tabata, H. Kimura, P. Wiedemann, and Y. Honda. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res. 23:253\u2013281 (2004). doi: 10.1016\/j.preteyeres.2004.02.003 .","journal-title":"Prog. Retin. Eye Res."},{"key":"9812_CR61","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.addr.2005.09.005","volume":"57","author":"T. Yasukawa","year":"2005","unstructured":"T. Yasukawa, Y. Ogura, E. Sakurai, Y. Tabata, and H. Kimura. Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev. 57:2033\u20132046 (2005). doi: 10.1016\/j.addr.2005.09.005 .","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9812_CR62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archopht.1992.01080140111037","volume":"110","author":"T. J. Smith","year":"1992","unstructured":"T. J. Smith, P. A. Pearson, D. L. Blandford, J. D. Brown, K. A. Goins, J. L. Hollins, E. T. Schmeisser, P. Glavinos, L. B. Baldwin, and P. Ashton. Intravitreal sustained-release ganciclovir. Arch. Ophthalmol. 110:255\u2013258 (1992).","journal-title":"Arch. Ophthalmol."},{"key":"9812_CR63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/1080768041223611","volume":"20","author":"J. Y. Driot","year":"2004","unstructured":"J. Y. Driot, G. D. Novack, K. D. Rittenhouse, C. Milazzo, and P. A. Pearson. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J. Ocul. Pharmacol. Ther. 20:269\u2013275 (2004). doi: 10.1089\/1080768041223611 .","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"9812_CR64","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/bjo.87.8.1032","volume":"87","author":"T. A. Ciulla","year":"2003","unstructured":"T. A. Ciulla, M. H. Criswell, R. P. Danis, M. Fronheiser, P. Yuan, T. A. Cox, K. G. Csaky, and M. R. Robinson. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. 87:1032\u20131037 (2003). doi: 10.1136\/bjo.87.8.1032 .","journal-title":"Br. J. Ophthalmol."},{"key":"9812_CR65","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jbm.a.30567","volume":"76","author":"N. R. Beeley","year":"2006","unstructured":"N. R. Beeley, J. M. Stewart, R. Tano, L. R. Lawin, R. A. Chappa, G. Qiu, A. B. Anderson, E. de Juan, and S. E. Varner. Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system. J. Biomed. Mater. Res. A. 76:690\u2013698 (2006). doi: 10.1002\/jbm.a.30567 .","journal-title":"J. Biomed. Mater. Res. A."},{"key":"9812_CR66","unstructured":"S. Varner. Coatings: sustained-release drug delivery for retinal disease, MDDI Archive, 2005."},{"key":"9812_CR67","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/00002512-200724070-00006","volume":"24","author":"B. A. Booth","year":"2007","unstructured":"B. A. Booth, L. Vidal Denham, S. Bouhanik, J. T. Jacob, and J. M. Hill. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Drugs Aging 24:581\u2013602 (2007). doi: 10.2165\/00002512-200724070-00006 .","journal-title":"Drugs Aging"},{"key":"9812_CR68","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/jbm.a.30294","volume":"73","author":"N. R. Beeley","year":"2005","unstructured":"N. R. Beeley, J. V. Rossi, P. A. Mello-Filho, M. I. Mahmoud, G. Y. Fujii, E. de Juan Jr., and S. E. Varner. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J. Biomed. Mater. Res. A 73:437\u2013444 (2005). doi: 10.1002\/jbm.a.30294 .","journal-title":"J. Biomed. Mater. Res. A."},{"key":"9812_CR69","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-3659(98)00061-3","volume":"55","author":"T. Zhou","year":"1998","unstructured":"T. Zhou, H. Lewis, R. E. Foster, and S. P. Schwendeman. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release 55:281\u2013295 (1998). doi: 10.1016\/S0168-3659(98)00061-3 .","journal-title":"J. Control. Release"},{"key":"9812_CR70","unstructured":"D. D. Lewis. Controlled release of bioactive agents from lactide\/glycolide polymers. In: M. Chasin and R. Langer (eds.), Biodegradable Polymers as Drug Delivery Systems, Biodegradable Polymers as Drug Delivery Systems, Marcel Dekker, New York, 1990."},{"key":"9812_CR71","first-page":"615","volume-title":"Physical Properties of Polymers","author":"L. J. Suggs","year":"1996","unstructured":"L. J. Suggs, and A. G. Mikos. Synthetic biodegradable polymers for medical applications. In E. Mark (ed.), Physical Properties of Polymers, American Institute of Physics, Woodbury, NY, 1996, pp. 615\u2013624."},{"key":"9812_CR72","first-page":"329","volume-title":"Handbook of Pharmaceutical Controlled Release Technology","author":"A. A. Hincal","year":"2000","unstructured":"A. A. Hincal, and S. Calis. Microsphere preparation by solvent evaporation method. In D. L. Wise (ed.), Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, New York, 2000, pp. 329\u2013343."},{"key":"9812_CR73","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2006.05.053","volume":"322","author":"O. Felt-Baeyens","year":"2006","unstructured":"O. Felt-Baeyens, S. Eperon, P. Mora, D. Limal, S. Sagodira, P. Breton, B. Simonazzi, L. Bossy-Nobs, Y. Guex-Crosier, and R. Gurny. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int. J. Pharm. 322:6\u201312 (2006). doi: 10.1016\/j.ijpharm.2006.05.053 .","journal-title":"Int. J. Pharm."},{"key":"9812_CR74","first-page":"161","volume-title":"Nanoparticles: Recent Developments, Vol. 4","author":"P. Breton","year":"1994","unstructured":"P. Breton, D. Roy, L. Marchal-Heussler, C. Seguin, P. Couvreur, and F. Lescure. New poly(methylidene malonate 2. 1. 2.). In G. Gregoriadis (ed.), Nanoparticles: Recent Developments, Vol. 4, Plenum, New York, 1994, pp. 161\u2013172."},{"key":"9812_CR75","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1023\/A:1018986226557","volume":"11","author":"F. Lescure","year":"1994","unstructured":"F. Lescure, C. Seguin, P. Breton, P. Bourrinet, D. Roy, and P. Couvreur. Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles. Pharm. Res. 11:1270\u20131277 (1994). doi: 10.1023\/A:1018986226557 .","journal-title":"Pharm. Res."},{"key":"9812_CR76","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijpharm.2007.10.054","volume":"352","author":"S. Eperon","year":"2008","unstructured":"S. Eperon, L. Bossy-Nobs, I. K. Petropoulos, R. Gurny, and Y. Guex-Crosier. A biodegradable drug delivery system for the treatment of postoperative inflammation. Int. J. Pharm. 352:240\u2013247 (2008).","journal-title":"Int. J. Pharm."},{"key":"9812_CR77","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0161-6420(99)90060-X","volume":"106","author":"D. T. Tan","year":"1999","unstructured":"D. T. Tan, S. P. Chee, L. Lim, and A. S. Lim. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 106:223\u2013231 (1999). doi: 10.1016\/S0161-6420(99)90060-X .","journal-title":"Ophthalmology"},{"key":"9812_CR78","first-page":"2318","volume":"37","author":"A. S. Berger","year":"1996","unstructured":"A. S. Berger, C. K. Cheng, P. A. Pearson, P. Ashton, P. A. Crooks, T. Cynkowski, G. Cynkowska, and G. J. Jaffe. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 37:2318\u20132325 (1996).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"9812_CR79","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1021\/jm010511b","volume":"45","author":"T. A. Macky","year":"2002","unstructured":"T. A. Macky, C. Oelkers, U. Rix, M. L. Heredia, E. Kunzel, M. Wimberly, B. Rohrer, C. E. Crosson, and J. Rohr. Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. J. Med. Chem. 45:1122\u20131127 (2002). doi: 10.1021\/jm010511b .","journal-title":"J. Med. Chem."},{"key":"9812_CR80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archopht.116.1.69","volume":"116","author":"C. S. Yang","year":"1998","unstructured":"C. S. Yang, J. A. Khawly, D. P. Hainsworth, S. N. Chen, P. Ashton, H. Guo, and G. J. Jaffe. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. 116:69\u201377 (1998).","journal-title":"Arch. Ophthalmol."},{"key":"9812_CR81","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1167\/iovs.02-0791","volume":"44","author":"U. B. Kompella","year":"2003","unstructured":"U. B. Kompella, N. Bandi, and S. P. Ayalasomayajula. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 44:1192\u2013201 (2003). doi: 10.1167\/iovs.02-0791 .","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"9812_CR82","first-page":"175","volume":"22","author":"B. Khoobehi","year":"1991","unstructured":"B. Khoobehi, M. O. Stradtmann, G. A. Peyman, and O. M. Aly. Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic. Surg. 22:175\u2013180 (1991).","journal-title":"Ophthalmic. Surg."},{"key":"9812_CR83","first-page":"3125","volume":"33","author":"T. Moritera","year":"1992","unstructured":"T. Moritera, Y. Ogura, N. Yoshimura, Y. Honda, R. Wada, S. H. Hyon, and Y. Ikada. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 33:3125\u20133130 (1992).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"9812_CR84","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1023\/A:1026464124412","volume":"17","author":"R. Herrero-Vanrell","year":"2000","unstructured":"R. Herrero-Vanrell, L. Ramirez, A. Fernandez-Carballido, and M. F. Refojo. . Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharm. Res. 17:1323\u20131328 (2000). doi: 10.1023\/A:1026464124412 .","journal-title":"Pharm. Res."},{"key":"9812_CR85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/02713689409167299","volume":"13","author":"H. Kimura","year":"1994","unstructured":"H. Kimura, Y. Ogura, T. Moritera, Y. Honda, Y. Tabata, and Y. Ikada. In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Curr. Eye Res. 13:353\u2013360 (1994).","journal-title":"Curr. Eye Res."},{"key":"9812_CR86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02713689408995774","volume":"13","author":"T. Moritera","year":"1994","unstructured":"T. Moritera, Y. Ogura, N. Yoshimura, S. Kuriyama, Y. Honda, Y. Tabata, and Y. Ikada. Feasibility of drug targeting to the retinal pigment epithelium with biodegradable microspheres. Curr. Eye Res. 13:171\u2013176 (1994). doi: 10.3109\/02713689408995774 .","journal-title":"Curr. Eye Res."},{"issue":"Suppl 1","key":"9812_CR87","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0039-6257(05)80069-4","volume":"39","author":"Y. Ogura","year":"1995","unstructured":"Y. Ogura, and H. Kimura. Biodegradable polymer microspheres for targeted drug delivery to the retinal pigment epithelium. Surv. Ophthalmol. 39(Suppl 1):S17\u201324 (1995). doi: 10.1016\/S0039-6257(05)80069-4 .","journal-title":"Surv. Ophthalmol."},{"key":"9812_CR88","first-page":"665","volume":"38","author":"A. A. Veloso Jr.","year":"1997","unstructured":"A. A. Veloso Jr., Q. Zhu, R. Herrero-Vanrell, and M. F. Refojo. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest. Ophthalmol. Vis. Sci. 38:665\u2013675 (1997).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"9812_CR89","first-page":"1785","volume":"32","author":"T. Moritera","year":"1991","unstructured":"T. Moritera, Y. Ogura, Y. Honda, R. Wada, S. H. Hyon, and Y. Ikada. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Vis. Sci. 32:1785\u20131790 (1991).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"9812_CR90","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4321\/S0365-66912006001200002","volume":"81","author":"J. A. Cardillo","year":"2006","unstructured":"J. A. Cardillo, A. A. Souza-Filho, and A. G. Oliveira. Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulness for the treatment of diabetic macular edema. Arch. Soc. Esp. Oftalmol. 81:675\u2013677 (2006). 679\u2013681.","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"9812_CR91","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archopht.1994.01090240037023","volume":"112","author":"D. F. Martin","year":"1994","unstructured":"D. F. Martin, D. J. Parks, and S. D. Mellow. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch. Ophthalmol. 112:1531\u20131539 (1994).","journal-title":"Arch. Ophthalmol"},{"key":"9812_CR92","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ophtha.2005.03.013","volume":"112","author":"G. J. Jaffe","year":"2005","unstructured":"G. J. Jaffe, R. M. McCallum, B. Branchaud, C. Skalak, Z. Butuner, and P. Ashton. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112:1192\u20131198 (2005). doi: 10.1016\/j.ophtha.2005.03.013 .","journal-title":"Ophthalmology"},{"key":"9812_CR93","first-page":"3569","volume":"41","author":"G. J. Jaffe","year":"2000","unstructured":"G. J. Jaffe, C. H. Yang, H. Guo, J. P. Denny, C. Lima, and P. Ashton. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol. Vis. Sci. 41:3569\u20133575 (2000).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"9812_CR94","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/archopht.1997.01100160559005","volume":"115","author":"D. F. Martin","year":"1997","unstructured":"D. F. Martin, F. L. Ferris, D. J. Parks, R. C. Walton, S. D. Mellow, D. Gibbs, N. A. Remaley, P. Ashton, M. D. Davis, C. C. Chan, and R. B. Nussenblatt. Ganciclovir implant exchange. Timing, surgical procedure, and complications. Arch. Ophthalmol. 115:1389\u20131394 (1997).","journal-title":"Arch. Ophthalmol."},{"key":"9812_CR95","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","volume":"142","author":"T. W. Olsen","year":"2006","unstructured":"T. W. Olsen, X. Feng, K. Wabner, S. R. Conston, D. H. Sierra, D. V. Folden, M. E. Smith, and J. D. Cameron. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am. J. Ophthalmol. 142:777\u2013787 (2006). doi: 10.1016\/j.ajo.2006.05.045 .","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR96","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0002-9394(14)78111-5","volume":"85","author":"L. D. Pizzarello","year":"1978","unstructured":"L. D. Pizzarello, F. A. Jakobiec, A. J. Hofeldt, M. M. Podolsky, and D. N. Silvers. Intralesional corticosteroid therapy of chalazia. Am. J. Ophthalmol. 85:818\u2013821 (1978).","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR97","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0161-6420(01)01018-1","volume":"109","author":"E. Zamir","year":"2002","unstructured":"E. Zamir, R. W. Read, R. E. Smith, R. C. Wang, and N. A. Rao. A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis. Ophthalmology 109:798\u2013805 (2002). discussion 805\u20137.","journal-title":"Ophthalmology"},{"key":"9812_CR98","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/bjo.87.8.968","volume":"87","author":"A. A. Okada","year":"2003","unstructured":"A. A. Okada, T. Wakabayashi, Y. Morimura, S. Kawahara, E. Kojima, Y. Asano, and T. Hida. Trans-Tenon\u2019s retrobulbar triamcinolone infusion for the treatment of uveitis. Br. J. Ophthalmol. 87:968\u2013971 (2003). doi: 10.1136\/bjo.87.8.968 .","journal-title":"Br. J. Ophthalmol."},{"key":"9812_CR99","first-page":"160","volume":"50","author":"S. Singh","year":"2001","unstructured":"S. Singh, V. Pal, and C. S. Dhull. Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis. Ind. J. Ophthalmol. 50:160\u2013161 (2001).","journal-title":"Ind. J. Ophthalmol."},{"key":"9812_CR100","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjo.2004.046193","volume":"88","author":"R. Ebner","year":"2004","unstructured":"R. Ebner, M. H. Devoto, D. Weil, M. Bordaberry, C. Mir, H. Martinez, L. Bonelli, and H. Niepomniszcze. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br. J. Ophthalmol. 88:1380\u20131386 (2004). doi: 10.1136\/bjo.2004.046193 .","journal-title":"Br. J. Ophthalmol."},{"key":"9812_CR101","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0002-9394(02)01938-4","volume":"135","author":"N. Benhamou","year":"2003","unstructured":"N. Benhamou, P. Massin, B. Haouchine, F. Audren, R. Tadayoni, and A. Gaudric. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am. J. Ophthalmol. 135:246\u2013249 (2003). doi: 10.1016\/S0002-9394(02)01938-4 .","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR102","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1600-0420.2006.00700.x","volume":"84","author":"F. Audren","year":"2006","unstructured":"F. Audren, A. Erginay, B. Haouchine, R. Benosman, J. Conrath, J. F. Bergmann, A. Gaudric, and P. Massin. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta. Ophthalmol. Scand. 84:624\u2013630 (2006). doi: 10.1111\/j.1600-0420.2006.00700.x .","journal-title":"Acta. Ophthalmol. Scand."},{"key":"9812_CR103","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archopht.122.8.1137","volume":"122","author":"Z. F. Bashshur","year":"2004","unstructured":"Z. F. Bashshur, R. N. Ma'luf, S. Allam, F. A. Jurdi, R. S. Haddad, and B. N. Noureddin. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch. Ophthalmol. 122:1137\u20131140 (2004). doi: 10.1001\/archopht.122.8.1137 .","journal-title":"Arch. Ophthalmol."},{"key":"9812_CR104","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archopht.122.8.1131","volume":"122","author":"M. S. Ip","year":"2004","unstructured":"M. S. Ip, J. L. Gottlieb, A. Kahana, I. U. Scott, M. M. Altaweel, B. A. Blodi, R. E. Gangnon, and C. A. Puliafito. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch. Ophthalmol. 122:1131\u20131136 (2004). doi: 10.1001\/archopht.122.8.1131 .","journal-title":"Arch. Ophthalmol."},{"key":"9812_CR105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00006982-200003000-00004","volume":"20","author":"R. P. Danis","year":"2000","unstructured":"R. P. Danis, T. A. Ciulla, L. M. Pratt, and W. Anliker. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244\u201350 (2000). doi: 10.1097\/00006982-200005000-00003 .","journal-title":"Retina"},{"key":"9812_CR106","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ajo.2004.05.073","volume":"138","author":"L. M. Smithen","year":"2004","unstructured":"L. M. Smithen, and R. F. Spaide. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am. J. Ophthalmol. 138:884\u2013885 (2004). doi: 10.1016\/j.ajo.2004.05.073 .","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR107","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9394(03)00389-1","volume":"136","author":"E. Rechtman","year":"2003","unstructured":"E. Rechtman, V. D. Allen, R. P. Danis, L. M. Pratt, A. Harris, and M. A. Speicher. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am. J. Ophthalmol. 136:739\u2013741 (2003). doi: 10.1016\/S0002-9394(03)00389-1 .","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR108","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ajo.2003.08.035","volume":"137","author":"R. E. Andrade","year":"2004","unstructured":"R. E. Andrade, C. Muccioli, M. E. Farah, R. B. Nussenblatt, and R. Belfort Jr. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt\u2013Koyanagi\u2013Harada syndrome. Am. J. Ophthalmol. 137:572\u2013574 (2004). doi: 10.1016\/j.ajo.2003.08.035 .","journal-title":"Am. J. Ophthalmol."},{"key":"9812_CR109","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00006982-200312000-00004","volume":"23","author":"C. Furino","year":"2003","unstructured":"C. Furino, T. Micelli Ferrari, F. Boscia, N. Cardascia, N. Recchimurzo, and C. Sborgia. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina 23:771\u2013776 (2003). doi: 10.1097\/00006982-200312000-00004 .","journal-title":"Retina"},{"key":"9812_CR110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0886-3350(03)00016-6","volume":"29","author":"S. E. Burk","year":"2003","unstructured":"S. E. Burk, A. P. Da Mata, M. E. Snyder, S. Schneider, R. H. Osher, and R. J. Cionni. Visualizing vitreous using Kenalog suspension. J. Cataract. Refract. Surg. 29:645\u2013651 (2003). doi: 10.1016\/S0886-3350(03)00016-6 .","journal-title":"J. Cataract. Refract. Surg."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-008-9812-z.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T15:18:17Z","timestamp":1558106297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-008-9812-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,28]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["9812"],"URL":"https:\/\/doi.org\/10.1007\/s11095-008-9812-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,28]]}}}